NVENTA ANNOUNCES FINAL DATA FROM HSPE7 PHASE 1 CERVICAL DYSPLASIA TRIAL

-- Company Provides Update to Phase 2 Development Plan --

FOR IMMEDIATE RELEASE - July 28, 2008

San Diego, California USA - Nventa Biopharmaceuticals Corporation (TSX:NVN) today announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial for HspE7, its lead product candidate. HspE7 is a therapeutic treatment for patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer. The primary cause of CIN is infection with certain human papillomavirus (HPV) types, of which HPV16 is the most common. Based on an analysis of HPV16 E7-specific T-cell responses across all cohorts, Nventa has identified a dose regimen of 500 mcg of HspE7 and 1,000-2,000 mcg of Poly-ICLC, a toll-like receptor 3 (TLR3) adjuvant, for subsequent Phase 2 trials.

The purpose of the Phase 1 trial was to determine the safety, tolerability and immunogenicity of HspE7 plus escalating doses of adjuvant (50, 500, 1,000 and 2,000 mcg of Poly-ICLC). All dose regimens were found to be safe and well tolerated. Immunogenicity analysis demonstrated that the adjuvant potently enhanced HPV16 E7-specific T-cell responses in subjects who demonstrated no or low responses at baseline.

“This Phase 1 trial has not only demonstrated HspE7’s excellent safety profile, it has also provided compelling data to support the immunologic activity of the compound and identified the appropriate dose regimen for our future trials,” said Gregory M. McKee, president and chief executive officer at Nventa. “We are very encouraged by these results and believe that HspE7 may offer an important therapeutic benefit for the millions of women with CIN.”

In the first cohort (500 mcg of HspE7 and 50 mcg of Poly-ICLC), which was designed to establish a baseline for the study, there was limited HPV16 E7-specific T-cell responses. In cohort 2 (500 mcg of HspE7 and 500 mcg of Poly-ICLC), three out of four patients showed HPV16 E7-specific T-cell responses. In the third cohort (500 mcg of HspE7 and 1,000 mcg of Poly-ICLC), HPV16 E7-specific T-cell responses were elicited in all four subjects and all of these T-cell responses represented significant changes from baseline, indicating that the responses were a direct result of treatment with HspE7. In the trial’s fourth and final cohort (500 mcg of HspE7 and 2,000 mcg of Poly-ICLC), two of five patients had significant increases in HPV16 E7-specific T-cells from baseline while the remaining three patients maintained high levels of HPV16 E7-specific T-cells that were already present at baseline. The absolute levels of HPV16 E7-specific T-cells in patients in the fourth cohort were similar to levels observed in the third cohort. The data, therefore, support doses of 500 mcg of HspE7 and 1,000-2,000 mcg of Poly-ICLC as appropriate for advancing into Phase 2 studies

Findings from this trial verify the company’s predicted mechanism of action for HspE7 as demonstrated by early preclinical models and support the compound’s potential to treat HPV16- induced CIN. HPV16 is the most common subtype of the HPV virus and is responsible for a significant percentage of cases of CIN.

Phase 2 Development Plan Update:

Following discussions with, and input from, the U.S. Food and Drug Administration (FDA), Nventa has finalized its protocol for a multi-center, randomized, double blind, placebo controlled Phase 2 trial of HspE7 in patients with high-grade cervical dysplasia (CIN 2/3). Preparations have been made at approximately 40 clinical investigational sites in the U.S., Canada and Latin America. The company has also designed a Phase 2 trial of HspE7 in patients with low-grade cervical dysplasia (CIN 1). Evaluation of clinical investigational sites in Europe and Latin America are underway. The company intends to initiate one or both of these Phase 2 trials once it has secured necessary financing.

About Cervical Intraepithelial Neoplasia (CIN):
CIN, also known as cervical dysplasia, is characterized by the presence in the cervix of abnormal cells that precede and can develop into cervical cancer. The primary cause of such abnormalities is infection with certain human papillomavirus (HPV) types, of which HPV16 is the most common. In the U.S., these infections are typically discovered through nearly 60 million Pap screens completed each year, at a cost of up to $6 billion. Each year in the U.S., an estimated 1.2 million women are diagnosed with low-grade cervical dysplasia (CIN 1), 300,000 with high-grade dysplasia (CIN 2/3) and 2.4 million with atypical squamous cells of undetermined significance (ASCUS). No therapies other than surgery are currently approved by the FDA for the treatment of any type of CIN.

About HspE7:
The company's lead product candidate, HspE7, is a novel therapeutic candidate intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 incorporates the proprietary adjuvant, Poly-ICLC, a toll-like receptor-3 (TLR3) agonist. An adjuvant is a substance added to vaccines to improve immune responses against target antigens. HspE7 is derived from Nventa's proprietary CoVal™ fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Nventa is developing HspE7 for multiple indications

About Nventa Corporation:
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by HPV. The company is publicly traded on the Toronto Stock Exchange under the symbol "NVN". For more information about Nventa, please visit www.nventacorp.com.

Contact:

Download a PDF file of this release